Occurrence of spontaneous pancreatic lesions in normal and diabetic rats: A potential confounding factor in the nonclinical assessment of GLP-1-based therapies

Diabetes

Volumn 63, Issue 4, 2014, Pages 1303-1314

  Chadwick, Kristina D ^a   Fletcher, Anthony M ^a   Parrula, M Cecilia ^a   Bonner Weir, Susan ^b   Mangipudy, Raja S ^a   Janovitz, Evan ^a   Graziano, Michael J ^a   Roy, Denis ^c   Reilly, Timothy P ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c AMYLIN PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALKALINE PHOSPHATASE; AMYLASE; AMYLIN; CHOLESTEROL; CREATININE; ELECTROLYTE; GLOBULIN; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; HEMOSIDERIN; INCRETIN; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; TRIACYLGLYCEROL; TRIACYLGLYCEROL LIPASE; UREA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATROPHY; CELL PROLIFERATION; CONTROLLED STUDY; DEGENERATION; DIABETES MELLITUS; ENZYME ACTIVITY; EXOCRINE GLAND; FOOD INTAKE; LIPID DIET; MALE; MORTALITY; NONHUMAN; PANCREAS DUCT; PANCREAS INJURY; PANCREAS LESION; PRIORITY JOURNAL; RAT; WEIGHT GAIN;

ANIMALS; DIABETES MELLITUS; DIET, HIGH-FAT; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; GLUCAGON-LIKE PEPTIDE 1; INCRETINS; PANCREAS; PANCREATIC DISEASES; PANCREATITIS; RATS; RATS, SPRAGUE-DAWLEY; RATS, ZUCKER; WEIGHT GAIN;

EID: 84897834466     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db13-1268     Document Type: Article

References (40)

1. World Health Organization. Diabetes [Internet]. World Health Organization, Geneva, Switzerland. Available from http://www.who.int/ mediacentre/factsheets/fs312/en/. Accessed March 12, 2013.
2. Cheung BM, Ong KL, Cherny SS, Sham PC, Tso AW, Lam KS. Diabetes prevalence and therapeutic target achievement in the United States, 1999 to 2006. Am J Med 2009;122:443-453
3. Dodd AH, Colby MS, Boye KS, Fahlman C, Kim S, Briefel RR. Treatment approach and HbA1c control among US adults with type 2 diabetes: NHANES 1999-2004. Curr Med Res Opin 2009;25:1605-1613
4. Inzucchi SE, Bergenstal RM, Buse JB, et al.; American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364-1379
5. Garber AJ, Abrahamson MJ, Barzilay JI, et al. AACE comprehensive diabetes management algorithm 2013. Endocr Pract 2013;19:327-336
6. Peterson G. Current treatments and strategies for type 2 diabetes: can we do better with GLP-1 receptor agonists? Ann Med 2012;44:338-349
7. Nachnani JS, Bulchandani DG, Nookala A, et al. Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas. Diabetologia 2010;53:153-159
8. Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 2011;141:150-156
9. Singh S, Chang H-Y, Richard TM, Weiner JP, Clark JM, Segal JB. Glucagon-like peptide-1-based therapies and the risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. JAMA Intern Med 2013;173:534-539
10. Butler AE, Campbell-Thompson M, Gurlo T, Dawson DW, Atkinson M, Butler PC. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes 2013;62:2595-2604
11. Matveyenko AV, Dry S, Cox HI, et al. Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin. Diabetes 2009;58:1604-1615
12. Gier B, Matveyenko AV, Kirakossian D, Dawson D, Dry SM, Butler PC. Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D) mouse model. Diabetes 2012;61:1250-1262
13. Yu X, Tang H, Huang L, Yang Y, Tian B, Yu C. Exenatide-induced chronic damage of pancreatic tissue in rats. Pancreas 2012;41:1235-1240
14. Butler AE, Jang J, Gurlo T, Carty MD, Soeller WC, Butler PC. Diabetes due to a progressive defect in beta-cell mass in rats transgenic for human islet amyloid polypeptide (HIP Rat): a new model for type 2 diabetes. Diabetes 2004;53:1509-1516
15. Wenten M, Gaebler JA, Hussein M, et al. Relative risk of acute pancreatitis in initiators of exenatide twice daily compared with other anti-diabetic medication: a follow-up study. Diabet Med 2012;29:1412-1418
16. Dore DD, Bloomgren GL, Wenten M, et al. A cohort study of acute pancreatitis in relation to exenatide use. Diabetes Obes Metab 2011;13:559-566
17. Garg R, Chen W, Pendergrass M. Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis. Diabetes Care 2010;33:2349-2354
18. Dore DD, Seeger JD, Arnold Chan K. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin 2009;25:1019-1027
19. Romley JA, Goldman DP, Solomon M, McFadden D, Peters AL. Exenatide therapy and the risk of pancreatitis and pancreatic cancer in a privately insured population. Diabetes Technol Ther 2012;14:904-911
20. Tatarkiewicz K, Smith PA, Sablan EJ, et al. Exenatide does not evoke pancreatitis and attenuates chemically induced pancreatitis in normal and diabetic rodents. Am J Physiol Endocrinol Metab 2010;299:E1076-E1086
21. Koehler JA, Baggio LL, Lamont BJ, Ali S, Drucker DJ. Glucagon-like peptide-1 receptor activation modulates pancreatitis-associated gene expression but does not modify the susceptibility to experimental pancreatitis in mice. Diabetes 2009;58:2148-2161
22. Nyborg NCB, Mølck A-M, Madsen LW, Knudsen LB. The human GLP-1 analog liraglutide and the pancreas: evidence for the absence of structural pancreatic changes in three species. Diabetes 2012;61:1243-1249
23. Vrang N, Jelsing J, Simonsen L, et al. The effects of 13 wk of liraglutide treatment on endocrine and exocrine pancreas in male and female ZDF rats: a quantitative and qualitative analysis revealing no evidence of drug-induced pancreatitis. Am J Physiol Endocrinol Metab 2012;303:E253-E264
24. Tatarkiewicz K, Belanger P, Gu G, Parkes D, Roy D. No evidence of drug-induced pancreatitis in rats treated with exenatide for 13 weeks. Diabetes Obes Metab 2013;15:417-426
25. Koehler JA, Drucker DJ. Activation of glucagon-like peptide-1 receptor signaling does not modify the growth or apoptosis of human pancreatic cancer cells. Diabetes 2006;55:1369-1379
26. Aston-Mourney K, Subramanian SL, Zraika S, et al. One year of sitagliptin treatment protects against islet amyloid-associated β-cell loss and does not induce pancreatitis or pancreatic neoplasia in mice. Am J Physiol Endocrinol Metab 2013;305:E475-E484
27. Forest T, Holder D, Smith A, Cunningham C, Dey M, Prahalada FC. Characterization of the exocrine pancreas in the Zucker diabetic fatty (ZDF) rat model of type 2 diabetes (T2DM) treated with sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor. Poster presented at the NIH-NIDDK Workshop on Pancreatitis-Diabetes-Pancreatic Cancer, 12-13 June 2013, Bethesda, Maryland
28. Fiorentino TV, Owston M, Abrahamian G, et al. Chronic continuous exenatide infusion does not cause pancreatitis or ductal hyperplasia in baboons. A 14 weeks longitudinal controlled study. Diabetes 2013;62(Suppl. 1):A263
29. European Medicines Agency. European Public Assessment Report (EPAR) for Galvus (vildagliptin). London, U.K., European Medicines Agency, 2007 (European Medicines Agency publication no. EMEA/H/C/771)
30. U.S. Food and Drug Administration. FDA Pharmacology/Toxicology Review for Byetta (exenatide, daily injection). Washington, DC, U.S. Govt. Printing Office, 2005 (NDA publication no. 21-773).
31. U.S. Food and Drug Administration. FDA Pharmacology/Toxicology Review for Januvia (sitagliptin). Washington, DC, U.S. Govt. Printing Office, 2005 (NDA publication no. 21-995).
32. U.S. Food and Drug Administration. FDA Pharmacology/Toxicology Review for Onglyza (saxagliptin). Washington, DC, U.S. Govt. Printing Office, 2009 (NDA publication no. 22-350)
33. U.S. Food and Drug Administration. FDA Pharmacology/Toxicology Review for Bydureon (exenatide weekly). Washington, DC, U.S. Govt. Printing Office, 2012 (NDA publication no. 22-200)
34. U.S. Food and Drug Administration. FDA Pharmacology/Toxicology Review for Tradjenta (linagliptin). Washington, DC, U.S. Govt. Printing Office, 2011 (NDA publication no. 20-1280)
35. U.S. Food and Drug Administration. FDA Pharmacology/Toxicology Review for Victoza (liraglutide). Washington, DC, U.S. Govt. Printing Office, 2010 (NDA publication no. 22-341)
36. U.S. Food and Drug Administration. FDA Pharmacology/Toxicology Review for Nesina (alogliptin). Washington, DC, U.S. Govt. Printing Office, 2012 (NDA publication no. 22-271)
37. Clark JB, Palmer CJ, Shaw WN. The diabetic Zucker fatty rat. Proc Soc Exp Biol Med 1983;173:68-75
38. Crissman JW, Goodman DG, Hildebrandt PK, et al. Best practices guideline: toxicologic histopathology. Toxicol Pathol 2004;32:126-131
39. Pound AW, Walker NI. Involution of the pancreas after ligation of the pancreatic ducts. I: a histological study. Br J Exp Pathol 1981;62:547-558
40. Watanabe S, Abe K, Anbo Y, Katoh H. Changes in the mouse exocrine pancreas after pancreatic duct ligation: a qualitative and quantitative histological study. Arch Histol Cytol 1995;58:365-374